Its cardiovascular safety profile compares favorably with that of  [[rosiglitazone]], which was withdrawn from some markets after concerns about an increased risk of cardiac events. Pioglitazone has been found to be associated with bladder tumors.<ref>{{cite web|last1=Commissioner|first1=Office of the|title=Safety Alerts for Human Medical Products - Pioglitazone-containing Medicines: Drug Safety Communication - Updated FDA Review, Increased Risk of Bladder Cancer|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm|website=www.fda.gov|accessdate=14 December 2016|language=en}}</ref> It has been withdrawn in some countries.

 

